Verve Therapeutics Halts Clinical Trial, Stock Plummets, Investors Sue

Verve Therapeutics, Inc. broke investors' hearts when its clinical trials of a novel drug flatlined. Now investors are returning the heartache, filing a class action lawsuit alleging that Verve executives knowingly misrepresented various aspects of the clinical trials.

Verve Therapeutics is a genetic medicine company specializing in cardiovascular care. In 2022, Verve announced the "Heart 1" clinical trials for VERVE-101, a novel drug designed to reduce LDL cholesterol. The Company also touted the superiority of its propriety delivery system for VERVE-101.

According to the lawsuit, when Company executives described the Heart-1 study to investors and analysts, they didn't announce the low threshold for calling off the whole study. Investors claim that executives had long-standing, undisclosed reservations about the delivery system's effectiveness and always knew they'd pull the plug on the program after any single adverse event.

In 2024, Investors learned the truth when the Company released a press release announcing that Verve had halted the Heart-1 trial due to a single adverse event. Shocked investors dumped Verve stock, causing it to lose 35% of its value overnight. Aggrieved investors are now joining the class-action lawsuit hoping to recoup some of their losses.

Join the Lawsuit.